Thymosin Beta-4 Research: The Actin-Binding Peptide Behind TB-500

What the published literature reports on thymosin beta-4: its 1981 sequencing, its role as an actin-sequestering peptide, AcSDKP and key animal studies.

Share

Thymosin beta-4, usually written Tβ4, is one of the most studied small peptides in cell biology. It was first sequenced as a thymus peptide, later turned out to be the main molecule that holds actin monomers in reserve inside cells, and then became the subject of high-profile animal studies on tissue repair. Much of the research-peptide interest in the name "TB-500" traces back to this literature. This overview walks through what the published papers actually report: the structure, the actin story, its metabolite AcSDKP, the main animal models, and the questions that remain. It is written for researchers and is not a guide to any use in people.

Discovery: a 43-residue peptide from calf thymus

Tβ4 came out of Allan Goldstein's thymosin program. In 1981, Low, Hu and Goldstein reported the complete amino acid sequence in the Proceedings of the National Academy of Sciences. According to the abstract, the polypeptide was isolated from calf thymus, is 43 amino acid residues long, has a molecular weight of 4,982 and an isoelectric point of 5.1, and carries an acetyl group blocking its N-terminus.

At the time it was framed as a thymic hormone. The same paper reported that it induced terminal deoxynucleotidyl transferase activity in transferase-negative mouse thymocytes, both in vivo and in vitro, and the authors suggested it might act on early stages of T-cell maturation. Tβ4 was one of several peptides found in a thymus extract called thymosin fraction 5.

For lab handling, a few structural facts matter. Tβ4 is acidic, relatively small, and has no disulfide bonds or stable folded core in isolation. It also contains a methionine at position 6, which becomes relevant below.

The actin story: Tβ4 is the platelet peptide "Fx"

The biggest shift in how researchers understood Tβ4 came ten years later. In 1991, Safer, Elzinga and Nachmias at the University of Pennsylvania published a short paper in the Journal of Biological Chemistry with a direct title: "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable."

Their starting point was a puzzle in platelets. At least half the actin in resting human platelets is unpolymerized, and most of that free actin was bound to an acidic, heat-stable 5-kDa peptide the group had named Fx. When they sequenced Fx, it was identical to Tβ4. Authentic Tβ4 behaved the same way: it formed a 1:1 complex with actin monomers (G-actin) and inhibited polymerization. Because Tβ4 is widespread and present at high concentration inside cells, the authors concluded it likely plays a significant role in regulating actin polymerization in many cell types.

This is the core biochemical fact about Tβ4. It is a G-actin sequestering peptide, which means it binds free actin monomers and keeps them from adding onto filaments until the cell needs them.

Oxidation changes activity: a handling lesson

A 1994 paper in the European Journal of Biochemistry by Heintz and colleagues at the Max Planck Institute in Heidelberg is useful for anyone working with Tβ4 material. In Tβ4 prepared from bovine lung, the peptide was accompanied by a form in which methionine-6 had been oxidized to its sulfoxide.

The sulfoxide inhibited actin polymerization about 20 times less than native Tβ4, matching a roughly 20-fold lower affinity for actin under polymerizing conditions. Under non-polymerizing conditions, however, its affinity was similar to the native peptide (about 1 micromolar). The authors noted the sulfoxide is presumably an autoxidation product.

The practical point is that a single oxidation event can measurably change how Tβ4 behaves in an actin assay. Methionine oxidation shows up as a +16 Da species by mass spectrometry, which is one reason identity testing and careful storage matter for this peptide. Our overview of peptide degradation pathways covers oxidation in more detail.

AcSDKP: a bioactive fragment from the N-terminus

Tβ4 is also a precursor. In 1990, Grillon and colleagues reported in FEBS Letters that the tetrapeptide AcSDKP (N-acetyl-Ser-Asp-Lys-Pro), described as a regulator of the hematopoietic system, can be generated from Tβ4 by a one-step enzymatic cleavage in vitro and in vivo. Both peptides were detected in bone marrow cells, and incubating radiolabelled Tβ4 with those cells produced labelled AcSDKP. Model digests with bacterial enzymes pointed to an endoproteinase Asp-N-type cleavage between Pro-4 and Asp-5.

This matters when interpreting experiments. An effect seen after adding Tβ4 to a biological system may come from the intact peptide, from AcSDKP, or from both.

Key animal and cell studies

Several frequently cited studies shaped the repair-focused research on Tβ4. They are summarized here as published, in the models used.

  • Skin wound model in rats (Malinda et al., 1999). In the Journal of Investigative Dermatology, NIH researchers reported that Tβ4, applied topically or intraperitoneally in a rat full-thickness wound model, increased re-epithelialization by 42% over saline controls at day 4 and by up to 61% at day 7. Treated wounds contracted at least 11% more by day 7, with more collagen deposition and angiogenesis. In a Boyden chamber assay, Tβ4 stimulated keratinocyte migration two- to three-fold.
  • Corneal alkali injury in mice (Sosne et al., 2002). In Experimental Eye Research, topical Tβ4 after alkali injury to mouse corneas was associated with faster re-epithelialization at all time points, less neutrophil infiltration at day 7, and several-fold lower mRNA levels of IL-1β and several chemokines compared with buffer-treated controls.
  • Cardiac cell migration and survival (Bock-Marquette et al., 2004). In Nature, a UT Southwestern group reported that Tβ4 promoted myocardial and endothelial cell migration in the embryonic heart, improved cardiomyocyte survival in culture, and formed a complex with PINCH and integrin-linked kinase (ILK) that activated the survival kinase Akt. After coronary artery ligation in mice, Tβ4 treatment was associated with improved cardiac function.
  • Epicardial progenitors and vessel formation (Smart et al., 2007). A UCL group reported in Nature that Tβ4 is essential for coronary vessel development in mice and stimulated outgrowth from adult mouse epicardial explants. Knocking down Tβ4 in the heart reduced AcSDKP levels, and AcSDKP enhanced endothelial differentiation from adult epicardial precursor cells.

A 2012 review in Expert Opinion on Biological Therapy by Goldstein, Hannappel, Sosne and Kleinman summarizes this body of work and describes Tβ4 as a multi-functional peptide involved in cell migration, angiogenesis and reduced inflammation in injury models.

Reading the literature carefully

A few cautions apply.

Models are specific. The repair findings above come from rodent wound, eye and heart models with particular injury methods and endpoints. They describe what happened in those models, not what happens elsewhere.

Mechanisms overlap. Actin sequestration, ILK-Akt signalling and AcSDKP generation are separate mechanisms. Many studies cannot say which one drives a given result.

"TB-500" is a market name, not a paper name. The studies above use full-length Tβ4. Material sold under the TB-500 name is not described consistently, so researchers should confirm from the certificate of analysis exactly what sequence and mass a vial contains before comparing it with published work. Our guide to reading a peptide COA explains what to check.

FAQ

How long is thymosin beta-4? The 1981 sequencing paper reported 43 amino acids, a molecular weight of 4,982 and an acetylated N-terminus.

What does Tβ4 do inside cells? It binds actin monomers in a 1:1 complex and inhibits their polymerization, acting as a reserve of unpolymerized actin.

What is AcSDKP? A four-residue fragment from the N-terminus of Tβ4, reported in 1990 to be generated from Tβ4 by enzymatic cleavage.

References

  • Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proceedings of the National Academy of Sciences USA. 1981;78(2):1162-1166. PMID: 6940133. doi:10.1073/pnas.78.2.1162.
  • Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991;266(7):4029-4032. PMID: 1999398.
  • Grillon C, Rieger K, Bakala J, et al. Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system. FEBS Letters. 1990;274(1-2):30-34. PMID: 2253778. doi:10.1016/0014-5793(90)81322-f.
  • Heintz D, Reichert A, Mihelic-Rapp M, et al. The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin. European Journal of Biochemistry. 1994;223(2):345-350. PMID: 8055902. doi:10.1111/j.1432-1033.1994.tb19000.x.
  • Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. PMID: 10469335. doi:10.1046/j.1523-1747.1999.00708.x.
  • Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research. 2002;74(2):293-299. PMID: 11950239. doi:10.1006/exer.2001.1125.
  • Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145. doi:10.1038/nature03000.
  • Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969. doi:10.1038/nature05383.
  • Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. PMID: 22074294. doi:10.1517/14712598.2012.634793.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.